PAPP-A and the IGF system in atherosclerosis: what's up, what's down?

Lasse B. Steffensen, Cheryl A. Conover, Claus Oxvig

Research output: Contribution to journalArticle

Abstract

Pregnancy-associated plasma protein-A (PAPP-A) is a metalloproteinase with a well-established role in releasing bioactive insulin-like growth factor-1 (IGF-1) from IGF-binding protein-2, -4, and -5 by proteolytic processing of these. The IGF system has repeatedly been suggested to be involved in the pathology of atherosclerosis, and both PAPP-A and IGF-1 are proposed biomarkers and therapeutic targets for this disease. Several experimental approaches based on atherosclerosis mouse models have been undertaken to obtain causative and mechanistic insight to the role of these molecules in atherogenesis. However, reports seem conflicting. The literature suggests that PAPP-A is detrimental, while IGF-1 is beneficial. This raises important questions that need to be addressed. Here we summarize the various studies and discuss potential underlying explanations for this seemingly inconsistency with the objective of better understanding complexities and limitations when manipulating the IGF system in mouse models of atherosclerosis. A debate clarifying what's up and what's down is highly warranted going forward with the ultimate goal of improving atherosclerosis therapy by targeting the IGF system.

Original languageEnglish (US)
Pages (from-to)H1039-H1049
JournalAmerican journal of physiology. Heart and circulatory physiology
Volume317
Issue number5
DOIs
StatePublished - Nov 1 2019

Fingerprint

Pregnancy-Associated Plasma Protein-A
Atherosclerosis
Somatomedins
Insulin-Like Growth Factor Binding Protein 4
Insulin-Like Growth Factor Binding Protein 2
Metalloproteases
Biomarkers
Pathology
Therapeutics

Keywords

  • atherosclerosis
  • IGF system
  • mouse models
  • PAPP-A

ASJC Scopus subject areas

  • Physiology
  • Cardiology and Cardiovascular Medicine
  • Physiology (medical)

Cite this

PAPP-A and the IGF system in atherosclerosis : what's up, what's down? / Steffensen, Lasse B.; Conover, Cheryl A.; Oxvig, Claus.

In: American journal of physiology. Heart and circulatory physiology, Vol. 317, No. 5, 01.11.2019, p. H1039-H1049.

Research output: Contribution to journalArticle

@article{124384eb14f846c6baafcbc1a341d770,
title = "PAPP-A and the IGF system in atherosclerosis: what's up, what's down?",
abstract = "Pregnancy-associated plasma protein-A (PAPP-A) is a metalloproteinase with a well-established role in releasing bioactive insulin-like growth factor-1 (IGF-1) from IGF-binding protein-2, -4, and -5 by proteolytic processing of these. The IGF system has repeatedly been suggested to be involved in the pathology of atherosclerosis, and both PAPP-A and IGF-1 are proposed biomarkers and therapeutic targets for this disease. Several experimental approaches based on atherosclerosis mouse models have been undertaken to obtain causative and mechanistic insight to the role of these molecules in atherogenesis. However, reports seem conflicting. The literature suggests that PAPP-A is detrimental, while IGF-1 is beneficial. This raises important questions that need to be addressed. Here we summarize the various studies and discuss potential underlying explanations for this seemingly inconsistency with the objective of better understanding complexities and limitations when manipulating the IGF system in mouse models of atherosclerosis. A debate clarifying what's up and what's down is highly warranted going forward with the ultimate goal of improving atherosclerosis therapy by targeting the IGF system.",
keywords = "atherosclerosis, IGF system, mouse models, PAPP-A",
author = "Steffensen, {Lasse B.} and Conover, {Cheryl A.} and Claus Oxvig",
year = "2019",
month = "11",
day = "1",
doi = "10.1152/ajpheart.00395.2019",
language = "English (US)",
volume = "317",
pages = "H1039--H1049",
journal = "American Journal of Physiology",
issn = "0363-6135",
publisher = "American Physiological Society",
number = "5",

}

TY - JOUR

T1 - PAPP-A and the IGF system in atherosclerosis

T2 - what's up, what's down?

AU - Steffensen, Lasse B.

AU - Conover, Cheryl A.

AU - Oxvig, Claus

PY - 2019/11/1

Y1 - 2019/11/1

N2 - Pregnancy-associated plasma protein-A (PAPP-A) is a metalloproteinase with a well-established role in releasing bioactive insulin-like growth factor-1 (IGF-1) from IGF-binding protein-2, -4, and -5 by proteolytic processing of these. The IGF system has repeatedly been suggested to be involved in the pathology of atherosclerosis, and both PAPP-A and IGF-1 are proposed biomarkers and therapeutic targets for this disease. Several experimental approaches based on atherosclerosis mouse models have been undertaken to obtain causative and mechanistic insight to the role of these molecules in atherogenesis. However, reports seem conflicting. The literature suggests that PAPP-A is detrimental, while IGF-1 is beneficial. This raises important questions that need to be addressed. Here we summarize the various studies and discuss potential underlying explanations for this seemingly inconsistency with the objective of better understanding complexities and limitations when manipulating the IGF system in mouse models of atherosclerosis. A debate clarifying what's up and what's down is highly warranted going forward with the ultimate goal of improving atherosclerosis therapy by targeting the IGF system.

AB - Pregnancy-associated plasma protein-A (PAPP-A) is a metalloproteinase with a well-established role in releasing bioactive insulin-like growth factor-1 (IGF-1) from IGF-binding protein-2, -4, and -5 by proteolytic processing of these. The IGF system has repeatedly been suggested to be involved in the pathology of atherosclerosis, and both PAPP-A and IGF-1 are proposed biomarkers and therapeutic targets for this disease. Several experimental approaches based on atherosclerosis mouse models have been undertaken to obtain causative and mechanistic insight to the role of these molecules in atherogenesis. However, reports seem conflicting. The literature suggests that PAPP-A is detrimental, while IGF-1 is beneficial. This raises important questions that need to be addressed. Here we summarize the various studies and discuss potential underlying explanations for this seemingly inconsistency with the objective of better understanding complexities and limitations when manipulating the IGF system in mouse models of atherosclerosis. A debate clarifying what's up and what's down is highly warranted going forward with the ultimate goal of improving atherosclerosis therapy by targeting the IGF system.

KW - atherosclerosis

KW - IGF system

KW - mouse models

KW - PAPP-A

UR - http://www.scopus.com/inward/record.url?scp=85074118307&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85074118307&partnerID=8YFLogxK

U2 - 10.1152/ajpheart.00395.2019

DO - 10.1152/ajpheart.00395.2019

M3 - Article

C2 - 31518159

AN - SCOPUS:85074118307

VL - 317

SP - H1039-H1049

JO - American Journal of Physiology

JF - American Journal of Physiology

SN - 0363-6135

IS - 5

ER -